Eyeworld Supplements

Therapeutic solutions: Ocular surface disease and episodic flares of dry eye disease ASCRS Elizabeth Yeu, MD, is assistant professor of ophthalmology, Eastern Virginia Medical School, and in private practice, Norfolk, Virginia. She has financial interests with Allergan, Alcon, Johnson & Johnson Vision, Kala Pharmaceu- ticals, Ocular Science, OCuSOFT, Science- Based Health, Shire, Sight Sciences, TearLab, and TissueTech. Eric Donnenfeld, MD, practices with Ophthal- mic Consultants of Long Island and Connecticut, and is clinical professor of ophthalmology, New York University, and trustee, Dartmouth Med- ical School. He has financial interests with Allergan, Alcon, Bausch + Lomb, and Kala Pharmaceuticals. Preeya Gupta, MD, is associate professor of ophthalmology, Duke University Eye Center, Durham, North Carolina. She has financial inter- ests with Alcon, Allergan, Aurea, Bausch + Lomb, Carl Zeiss Meditec, Johnson & Johnson Vi- sion, Kala Pharmaceuticals, NovaBay Pharma- ceuticals, Novartis, Ocular Science, Omeros, Takeda, and TearLab. Edward Holland, MD, is professor of ophthal- mology, University of Cincinnati. He has finan- cial interests with Kala Pharmaceuticals and Takeda Pharmaceuticals. Terry Kim, MD, is professor of ophthal- mology, chief of the Cornea and External Disease Division, and director of the Refractive Surgery Service, Duke University Eye Center, Durham, North Carolina. He has financial interests with Allergan, Johnson & Johnson Vision, Kala Pharmaceuticals, and Shire. Richard Lindstrom, MD, is founder of Min- nesota Eye Consultants, and adjunct professor emeritus, Department of Ophthalmology and Visual Neurosciences, University of Minnesota, Minneapolis. He has financial interests with Alcon, Allegro, Allergan, Bausch + Lomb, Carl Zeiss Meditec, Imprimis, Johnson & Johnson Vision, Kala Pharmaceuticals, Ocular Therapeutix, and TearLab. This supplement is independently supported by Kala Medical Affairs. EyeWorld recently gath- ered ocular surface disease (OSD) experts to discuss clinical rec- ommendations for acute exacerbations of dry eye disease. Participants discussed evolving thera- peutic solutions to im- prove understanding of the signs and symptoms associated with episodic flares of OSD, making therapeutic decisions for patients through variable stages of OSD, unmet needs, and the relevance and mechanism of action (MOA) of mucus-penetrat- ing nanoparticles (MPP). Eric Donnenfeld, MD, moderated the panel, which included Edward Holland, MD, Richard Lindstrom, MD, Elizabeth Yeu, MD, Preeya Gupta, MD, and Terry Kim, MD.

• Cover